41 results about "Retinal pigment epithelium cell" patented technology

Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

The invention discloses a preparation and amplification culture method of human multipotential stem cell sourced human retinal pigment epithelium cells. The method comprises the following steps of collecting a 3D-RPE sphere from the human multipotential stem cell sources; performing mechanical separation, removing non-RPE cells or agglomerates containing no pigments; remaining RPE cell sheets containing the pigments; performing enzymolysis digestion on the pigment-containing RPE cell sheets to obtain RPE unicellular suspension; thus obtaining the human multipotential stem cell sourced human retinal pigment epithelium cells. The features of the human RPE cells prepared by the method are similar to the features of human embryo sourced RPE cells; the typical RPE cell form features are realized; the normal physiological functions are shown. The human RPE cells prepared by the method can realize the subculture; the mass amplification is realized; the seed cells are provided for the study and treatment of retinal diseases; benefits are brought to blind patients; the problem of important defects of limited retinal pigment epithelium cells and RPE transplanting donor lack in the prior artcan be solved; great significance is realized.

Disclosed is a complex for remedying or treating a retinal disease. The complex includes a hyaluronic acid or a derivative thereof, a carbon nanomaterial covalently bonded to the hyaluronic acid or the derivative thereof, and a photosensitizer bonded to the carbon nanomaterial. The complex for remedying or treating the retinal disease according to the present invention includes a hyaluronic acid-carbon nanomaterial-photosensitizer complex, thus selectively preventing the formation of active oxygen in retinal pigment epithelium cells for a relatively long period of time. Accordingly, the complex has excellent therapeutic efficacy and easily infiltrates into cells. Further, the present invention provides a composition for remedying or treating a retinal disease including the hyaluronic acid-carbon nanomaterial-photosensitizer complex.

Provided herein are methods of producing an RPE cell population from a starting cell suspension, such as a single cell suspension, of pluripotent stem cells (PSCs). Such a method may comprise culturing the starting single cell suspension of PSCs in differentiation media to produce human RPE cells.

This invention relates to novel method of treating or ameliorating a retinal disease or disorder or retinal degradation in a subject and a novel method of restoring retinal pigment epithelium cell compromising the administration of a one or more compounds which modulate Nox4, formation of radical oxygen species, serine protease, a dopamine receptor, NF-kB, mTOR, AMPK, RPE epithelial to mesenchymal transition, RPE dedifferentiation, or one or more Rho GTPases; and kits for administration of the methods.

The invention relates to the technical field of biology, in particular to a preparation method and application of recombinant VEGFB (vascular endothelial growth factor B). The preparation method of the recombinant VEGFB mainly comprises a purification method of the recombinant VEGFB and comprises the steps of inclusion body dissolution, affinity chromatography purification, renaturation and gel filtration chromatography, and the recombinant VEGFB obtained through purification not only has good yield and purity, but also has good physiological activity and has a good protection effect on retinal pigment epithelial cells.

The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

The invention provides application of thrombospondin 1 (THBS-1) in preparation of a medicine for preventing and/or treating age-related macular degeneration (AMD), and belongs to the technical field of eye disease medicines. As the pathological process of the AMD comprises injury and death of retinal pigment epithelium (RPE), formation of choroidal neovascularization (CNV) and retinal inflammation, in-vitro cell experiments and in-vivo animal experiments are combined to verify the anti-inflammatory effect of the THBS-1 in experimental blue light induced retinal inflammation and verify the effect of the THBS-1 in inhibition of pathological neovascularization and the protection effect of retinal injury. Therefore, the invention provides the application of the THBS-1 in preparation of the medicine for preventing and/or treating the AMD.

The invention belongs to the field of pharmacy, disclosing a novel purpose of lipoamide which is used for preparing a preparation for preventing or curing diseases being relevant to cell trauma. The invention discloses the novel purpose at the aspect of preventing and curing cell trauma for the first time; in addition, the extremely effective easing and curing function of the lipoamide to the trauma of retinal pigment epithelium cell is disclosed for the first time, the pharmacological actions are very obvious, no any toxic and side effects appear and the admirable medicated prospect can be reached.